Sort by:
Millar DG, Ramjiawan RR, Kawaguchi K, Gupta N, Chen J, Zhang S, Nojiri T, Ho WW, Aoki S, Jung K, Chen I, Shi F, Heather JM, Shigeta K, Morton LT, Sepulveda S, Wan L, Joseph R, Minogue E, Khatri A, Bardia A, Ellisen LW, Corcoran RB, Hata AN, Pai SI, Jain RK, Fukumura D, Duda DG, Cobbold M
Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy.
Nat Biotechnol. 2020;38(4):420-425 - PMID: 32042168 - PMCID: PMC7456461 - DOI: 10.1038/s41587-019-0404-8
Gastman B, Agarwal PK, Berger A, Boland G, Broderick S, Butterfield LH, Byrd D, Fecci PE, Ferris RL, Fong Y, Goff SL, Grabowski MM, Ito F, Lim M, Lotze MT, Mahdi H, Malafa M, Morris CD, Murthy P, Neves RI, Odunsi A, Pai SI, Prabhakaran S, Rosenberg SA, Saoud R, Sethuraman J, Skitzki J, Slingluff CL, Sondak VK, Sunwoo JB, Turcotte S, Yeung CC, Kaufman HL
Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee.
J Immunother Cancer. 2020;8(2):ePub - PMID: 33199512 - PMCID: PMC7670953 - DOI: 10.1136/jitc-2020-001583
Mahmood U, Bang A, Chen YH, Mak RH, Lorch JH, Hanna GJ, Nishino M, Manuszak C, Thrash EM, Severgnini M, Sanborn M, Sridharan V, Margalit DN, Tishler RB, Busse PM, Willers H, Mamon HJ, Yoo HJ, Pai SI, Wirth LJ, Haddad RI, Chau NG, Schoenfeld JD
A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma.
Int J Radiat Oncol Biol Phys. 2020;109(1):134-144 - PMID: 32781104 - PMCID: PMC9361179 - DOI: 10.1016/j.ijrobp.2020.08.018
Pai SI, Faquin WC, Sadow PM, Pittet MJ, Weissleder R
New Technology on the Horizon: Fast Analytical Screening Technique FNA (FAST-FNA) Enables Rapid, Multiplex Biomarker Analysis in Head and Neck Cancers
Cancer Cytopathol. 2020;128(11):782-791 - PMID: 32841527 - PMCID: PMC8276888 - DOI: 10.1002/cncy.22305
Wolkow N, Jakobiec FA, Afrogheh AH, Pai SI, Faquin WC
High Expression of Programmed Death Ligand 1 and Programmed Death Ligand 2 in Ophthalmic Sebaceous Carcinoma: The Case for a Clinical Trial of Checkpoint Inhibitors.
Am J Ophthalmol. 2020;220:128-139 - PMID: 32730911 - PMCID: PMC9361189 - DOI: 10.1016/j.ajo.2020.07.031
Wolkow N, Jakobiec FA, Afrogheh AH, Kidd M, Eagle RC, Pai SI, Faquin WC
PD-L1 and PD-L2 Expression Levels Are Low in Primary and Secondary Adenoid Cystic Carcinomas of the Orbit: Therapeutic Implications.
Ophthalmic Plast Reconstr Surg. 2020;36(5):444-450 - PMID: 31990894 - PMCID: PMC7423458 - DOI: 10.1097/IOP.0000000000001585
Pai SI, Cesano A, Marincola FM
The Paradox of Cancer Immune Exclusion: Immune Oncology Next Frontier.
Cancer Treat Res. 2020;180:173-195 - PMID: 32215870 - PMCID: PMC7423459 - DOI: 10.1007/978-3-030-38862-1_6
7 CSV